Ikena Oncology (IKNA)

• Market cap: $65.1M
• 1 day: -1.46%
• 5 days: -9.40%
• 1 month: 16.38%
• 3 months: -0.74%
• 6 months: -18.18%
• Year to date: -18.18%
• 1 year: -23.73%
• 5 years: -95.78%
• 10 years: -95.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Employees: 9

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

0.59% less ownership

Funds ownership: 78.77% [Q4 2024] → 78.18% (-0.59%) [Q1 2025]

13% less funds holding

Funds holding: 53 [Q4 2024] → 46 (-7) [Q1 2025]

19% less capital invested

Capital invested by funds: $52M [Q4 2024] → $41.9M (-$10.1M) [Q1 2025]

65% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 20

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10